Entering text into the input field will update the search result below

Advaxis teams up with Merck in prostate cancer

Aug. 25, 2014 10:46 AM ETAyala Pharmaceuticals, Inc. (ADXS) StockBy: Douglas W. House, SA News Editor1 Comment
  • Shares of nan cap Advaxis (OTC:ADXS +12.9%) jump on a 6x surge in volume in response to its announcement of a clinical trial collaboration with Merck (MRK +1%) that will evaluate the combination of Advaxis' Lm-LLO cancer immunotherapy, ADXS-PSA with Merck's investigational anti PD-1 Ab, pembrolizumab.
  • The Phase 1/2 trial will assess the safety and efficacy of ADXS-PSA as monotherapy and in combination with pembrolizumab in patients with previously treated metastatic castration-resistant prostate cancer.
  • The Phase 1 segment is designed to establish a dose regimen for ADXS-PSA alone. The Phase 2 segment will assess the safety and efficacy of the combination. The trial will commence in early 2015. The results will determine if further development is warranted.

Recommended For You

About ADXS Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
ADXS--
Ayala Pharmaceuticals, Inc.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.